We are live on ! Find out more
SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

Fund managers haven’t disclosed any holdings of SYRS yet.

SYRS Hedge Fund Activity: Q2 2025 in Review

0 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2025, worth a combined $0 — down 100% from $12.4K a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of SYRS and 0 opened new positions — a net loss of 7 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Acadian Asset Management, exiting entirely with an estimated $9K sold.

  • 0 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2025, down from 7 in Q1 2025.
  • Funds reported $0 of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2025 and 7 closed out, a net change of -7 holders.
  • The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q2 2025 was Acadian Asset Management, an estimated $9K sold.

Based on aggregated 13F filings for Q2 2025.